Dysregulation of Neurotrophic and Haematopoietic Growth Factors in Alzheimer's Disease: From Pathophysiology to Novel Treatment Strategies

Current Alzheimer Research

Volumn 11, Issue 1, 2014, Pages 27-39

  Sopova, Kateryna ^a,b   Gatsiou, Katerina ^c   Stellos, Konstantinos ^c   Laske, Christoph ^a,d,e  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b SLK Kliniken Heilbronn GmbH   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Alzheimer's disease; BBB; G CSF; Growth factors; SCF

Indexed keywords

ANGIOPOIETIN 1; BRAIN DERIVED NEUROTROPHIC FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; NERVE GROWTH FACTOR; NEURITE PROMOTING FACTOR; NEUROTROPHIC FACTOR; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN;

ALZHEIMER DISEASE; ANGIOGENESIS; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; HOMEOSTASIS; HUMAN; NERVOUS SYSTEM DEVELOPMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; NERVE GROWTH FACTORS; NEUROGENESIS;

EID: 84891818861     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205010666131120100743     Document Type: Article

References (184)

1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81(2): 741-766 (2001).
2. Cummings JL. Alzheimer's disease. N Engl J Med 351(1): 56-67 (2004).
3. Kawada H, Takizawa S, Takanashi T, Morita Y, Fujita J, Fukuda K, et al. Administration of hematopoietic cytokines in the subacute phase after cerebral infarction is effective for functional recovery facilitating proliferation of intrinsic neural stem/progenitor cells and transition of bone marrow-derived neuronal cells. Circulation 113(5): 701-710 (2006).
4. Piltonen M, Bespalov MM, Ervasti D, Matilainen T, Sidorova YA, Rauvala H, et al. Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. Exp Neurol 219(2): 499-506 (2009).
5. Schabitz WR, Steigleder T, Cooper-Kuhn CM, Schwab S, Sommer C, Schneider A, et al. Intravenous brain-derived neurotrophic factor enhances poststroke sensorimotor recovery and stimulates neurogenesis. Stroke 38(7): 2165-2172 (2007).
6. Schanzer A, Wachs FP, Wilhelm D, Acker T, Cooper-Kuhn C, Beck H, et al. Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol 14(3): 237-248 (2004).
7. Siegel GJ, Chauhan NB. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Brain Res Rev 33(2-3): 199-227 (2000).
8. Risau W, Wolburg H. Development of the blood-brain barrier. Trends Neurosci 13(5): 174-8 (1990).
9. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7(1): 41-53 (2006).
10. Viggars AP, Wharton SB, Simpson JE, Matthews FE, Brayne C, Savva GM, et al. Alterations in the blood brain barrier in ageing cerebral cortex in relationship to Alzheimer-type pathology: a study in the MRC-CFAS population neuropathology cohort. Neurosci Lett 505(1): 25-30 (2011).
11. Starr JM, Farrall AJ, Armitage P, McGurn B, Wardlaw J. Bloodbrain barrier permeability in Alzheimer's disease: a case-control MRI study. Psychiatry Res 171(3): 232-241 (2009).
12. Bell RD, Zlokovic BV. Neurovascular mechanisms and bloodbrain barrier disorder in Alzheimer's disease. Acta Neuropathol 118(1): 103-113 (2009).
13. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 5(5): 347-360 (2004).
14. Stanimirovic DB, Friedman A. Pathophysiology of the neurovascular unit: disease cause or consequence? J Cereb Blood Flow Metab 32(7): 1207-1221 (2012).
15. Rosenberg GA. Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab 32(7): 1139-1151 (2012).
16. Biron KE, Dickstein DL, Gopaul R, Jefferies WA. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. PLoS One 6(8): e23789 (2011).
17. Winkler DT, Bondolfi L, Herzig MC, Jann L, Calhoun ME, Wiederhold KH, et al. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci 21(5): 1619-1627 (2001).
18. Sharma HS, Castellani RJ, Smith MA, Sharma A. The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery. Int Rev Neurobiol 102: 47-90 (2012).
19. Paris D, Patel N, DelleDonne A, Quadros A, Smeed R, Mullan M. Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci Lett 366(1): 80-5 (2004).
20. Biron KE, Dickstein DL, Gopaul R, Fenninger F, Jefferies WA. Cessation of Neoangiogenesis in Alzheimer's Disease Follows Amyloid-beta Immunization. Sci Rep 3: 1354 (2013).
21. Jin K, Galvan V, Xie L, Mao XO, Gorostiza OF, Bredesen DE, et al. Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw,Ind) mice. Proc Natl Acad Sci USA 101(36): 13363-7 (2004).
22. Lopez-Toledano MA, Shelanski ML. Increased neurogenesis in young transgenic mice overexpressing human APP(Sw, Ind). J Alzheimers Dis 12(3): 229-240 (2007).
23. Jin K, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, et al. Increased hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci USA 101(1): 343-7 (2004).
24. Boekhoorn K, Joels M, Lucassen PJ. Increased proliferation reflects glial and vascular-associated changes, but not neurogenesis in the presenile Alzheimer hippocampus. Neurobiol Dis 24(1): 1-14 (2006).
25. Ziabreva I, Perry E, Perry R, Minger SL, Ekonomou A, Przyborski S, et al. Altered neurogenesis in Alzheimer's disease. J Psychosom Res 61(3): 311-6 (2006).
26. Verwer RW, Sluiter AA, Balesar RA, Baayen JC, Noske DP, Dirven CM, et al. Mature astrocytes in the adult human neocortex express the early neuronal marker doublecortin. Brain 130(Pt 12): 3321-3335 (2007).
27. Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by secreted proneurotrophins. Science 294(5548): 1945-8 (2001).
28. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 72: 609-642 (2003).
29. Hempstead BL. The many faces of p75NTR. Curr Opin Neurobiol 12(3): 260-7 (2002).
30. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 189(5): 865-870 (1999).
31. Nakahashi T, Fujimura H, Altar CA, Li J, Kambayashi J, Tandon NN, et al. Vascular endothelial cells synthesize and secrete brainderived neurotrophic factor. FEBS Lett 470(2): 113-117 (2000).
32. Donovan MJ, Miranda RC, Kraemer R, McCaffrey TA, Tessarollo L, Mahadeo D, et al. Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury. Am J Pathol 147(2): 309-324 (1995).
33. Donovan MJ, Lin MI, Wiegn P, Ringstedt T, Kraemer R, Hahn R, et al. Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development 127(21): 4531-4540 (2000).
34. Matsuda S, Fujita T, Kajiya M, Takeda K, Shiba H, Kawaguchi H, et al. Brain-derived neurotrophic factor induces migration of endothelial cells through a TrkB-ERK-integrin alphaVbeta3-FAK cascade. J Cell Physiol 227(5): 2123-9 (2012).
35. Lam CT, Yang ZF, Lau CK, Tam KH, Fan ST, Poon RT. Brainderived neurotrophic factor promotes tumorigenesis via induction of neovascularization: implication in hepatocellular carcinoma. Clin Cancer Res 17(10): 3123-3133 (2011).
36. Qin L, Kim E, Ratan R, Lee FS, Cho S. Genetic variant of BDNF (Val66Met) polymorphism attenuates stroke-induced angiogenic responses by enhancing anti-angiogenic mediator CD36 expression. J Neurosci 31(2): 775-783 (2011).
37. Kermani P, Rafii D, Jin DK, Whitlock P, Schaffer W, Chiang A, et al. Neurotrophins promote revascularization by local recruitment of TrkB+ endothelial cells and systemic mobilization of hematopoietic progenitors. J Clin Invest 115(3): 653-663 (2005).
38. Yan Q, Radeke MJ, Matheson CR, Talvenheimo J, Welcher AA, Feinstein SC. Immunocytochemical localization of TrkB in the central nervous system of the adult rat. J Comp Neurol 378(1): 135-157 (1997).
39. Levine ES, Crozier RA, Black IB, Plummer MR. Brain-derived neurotrophic factor modulates hippocampal synaptic transmission by increasing N-methyl-D-aspartic acid receptor activity. Proc Natl Acad Sci USA 95(17): 10235-9 (1998).
40. Lee J, Duan W, Mattson MP. Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J Neurochem 82(6): 1367-1375 (2002).
41. Lopatina T, Kalinina N, Karagyaur M, Stambolsky D, Rubina K, Revischin A, et al. Adipose-derived stem cells stimulate regeneration of peripheral nerves: BDNF secreted by these cells promotes nerve healing and axon growth de novo. PLoS One 6(3): e17899 (2011).
42. Peng S, Garzon DJ, Marchese M, Klein W, Ginsberg SD, Francis BM, et al. Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J Neurosci 29(29): 9321-9 (2009).
43. Laske C, Stransky E, Leyhe T, Eschweiler GW, Wittorf A, Richartz E, et al. Stage-dependent BDNF serum concentrations in Alzheimer's disease. J Neural Transm 113(9): 1217-1224 (2006).
44. O'Bryant SE, Hobson VL, Hall JR, Barber RC, Zhang S, Johnson L, et al. Serum brain-derived neurotrophic factor levels are specifically associated with memory performance among Alzheimer's disease cases. Dement Geriatr Cogn Disord 31(1): 31-36 (2011).
45. Laske C, Stransky E, Leyhe T, Eschweiler GW, Schott K, Langer H, et al. Decreased brain-derived neurotrophic factor (BDNF)- and beta-thromboglobulin (beta-TG)- blood levels in Alzheimer's disease. Thromb Haemost 96(1): 102-3 (2006).
46. Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, et al. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res 41(5): 387-394 (2007).
47. Leyhe T, Stransky E, Eschweiler GW, Buchkremer G, Laske C. Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 258(2): 124-8 (2008).
48. Leyhe T, Eschweiler GW, Stransky E, Gasser T, Annas P, Basun H, et al. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J Alzheimers Dis 16(3): 649-656 (2009).
49. Timmusk T, Palm K, Metsis M, Reintam T, Paalme V, Saarma M, et al. Multiple promoters direct tissue-specific expression of the rat BDNF gene. Neuron 10(3): 475-489 (1993).
50. Garzon D, Yu G, Fahnestock M. A new brain-derived neurotrophic factor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer's disease parietal cortex. J Neurochem 82(5): 1058-1064 (2002).
51. Cantarella G, Lempereur L, Presta M, Ribatti D, Lombardo G, Lazarovici P, et al. Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J 16(10): 1307-9 (2002).
52. Manni L, Antonelli A, Costa N, Aloe L. Stress alters vascularendothelial growth factor expression in rat arteries: role of nerve growth factor. Basic Res Cardiol 100(2): 121-130 (2005).
53. Berger K, Breteler MM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, et al. Prognosis with Parkinson's disease in europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54(11): S24-S27 (2000).
54. Khan KM, Falcone DJ, Kraemer R. Nerve growth factor activation of Erk-1 and Erk-2 induces matrix metalloproteinase-9 expression in vascular smooth muscle cells. J Biol Chem 277(3): 2353-9 (2002).
55. Meloni M, Descamps B, Caporali A, Zentilin L, Floris I, Giacca M, et al. Nerve growth factor gene therapy using adeno-associated viral vectors prevents cardiomyopathy in type 1 diabetic mice. Diabetes 61(1): 229-240 (2012).
56. Levi-Montalcini R. The nerve growth factor 35 years later. Science 237(4819): 1154-1162 (1987).
57. Cattaneo E, McKay R. Proliferation and differentiation of neuronal stem cells regulated by nerve growth factor. Nature 347(6295): 762-5 (1990).
58. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 24: 1217-1281 (2001).
59. Debeir T, Saragovi HU, Cuello AC. A nerve growth factor mimetic TrkA antagonist causes withdrawal of cortical cholinergic boutons in the adult rat. Proc Natl Acad Sci USA 96(7): 4067-4072 (1999).
60. Davies SW, Beardsall K. Nerve growth factor selectively prevents excitotoxin induced degeneration of striatal cholinergic neurones. Neurosci Lett 140(2): 161-4 (1992).
61. Cheng B, Mattson MP. NGF and bFGF protect rat hippocampal and human cortical neurons against hypoglycemic damage by stabilizing calcium homeostasis. Neuron 7(6): 1031-1041 (1991).
62. Luo J, West JR, Pantazis NJ. Nerve growth factor and basic fibroblast growth factor protect rat cerebellar granule cells in culture against ethanol-induced cell death. Alcohol Clin Exp Res 21(6): 1108-1120 (1997).
63. Lee HJ, Lim IJ, Park SW, Ko YB, Kim SU. Human neural stem cells genetically modified to express human nerve growth factor (NGF) gene restore cognition in mouse with ibotenic acid-induced cognitive dysfunction. Cell Transplant: 21(11): 2487-2496 (2012).
64. Pechan PA, Yoshida T, Panahian N, Moskowitz MA, Breakefield XO. Genetically modified fibroblasts producing NGF protect hippocampal neurons after ischemia in the rat. Neuroreport 6(4): 669-672 (1995).
65. Gall CM, Isackson PJ. Limbic seizures increase neuronal production of messenger RNA for nerve growth factor. Science 245(4919): 758-761 (1989).
66. Kordower JH, Winn SR, Liu YT, Mufson EJ, Sladek JR, Jr., Hammang JP, et al. The aged monkey basal forebrain: rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor. Proc Natl Acad Sci USA 91(23): 10898-10902 (1994).
67. Schmid-Brunclik N, Burgi-Taboada C, Antoniou X, Gassmann M, Ogunshola OO. Astrocyte responses to injury: VEGF simultaneously modulates cell death and proliferation. Am J Physiol Regul Integr Comp Physiol 295(3): R864-R873 (2008).
68. Allard S, Leon WC, Pakavathkumar P, Bruno MA, Ribeiro-da- Silva A, Cuello AC. Impact of the NGF maturation and degradation pathway on the cortical cholinergic system phenotype. J Neurosci 32(6): 2002-2012 (2012).
69. Greferath U, Bennie A, Kourakis A, Bartlett PF, Murphy M, Barrett GL. Enlarged cholinergic forebrain neurons and improved spatial learning in p75 knockout mice. Eur J Neurosci 12(3): 885-93 (2000).
70. Bruno MA, Cuello AC. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc Natl Acad Sci USA 103(17): 6735-6740 (2006).
71. Shigeno T, Mima T, Takakura K, Graham DI, Kato G, Hashimoto Y, et al. Amelioration of delayed neuronal death in the hippocampus by nerve growth factor. J Neurosci 11(9): 2914-9 (1991).
72. Mobley WC, Rutkowski JL, Tennekoon GI, Buchanan K, Johnston MV. Choline acetyltransferase activity in striatum of neonatal rats increased by nerve growth factor. Science 229(4710): 284-7 (1985).
73. Chen KS, Nishimura MC, Armanini MP, Crowley C, Spencer SD, Phillips HS. Disruption of a single allele of the nerve growth factor gene results in atrophy of basal forebrain cholinergic neurons and memory deficits. J Neurosci 17(19): 7288-7296 (1997).
74. Mobley WC, Neve RL, Prusiner SB, McKinley MP. Nerve growth factor increases mRNA levels for the prion protein and the betaamyloid protein precursor in developing hamster brain. Proc Natl Acad Sci USA 85(24): 9811-5 (1988).
75. Milward EA, Papadopoulos R, Fuller SJ, Moir RD, Small D, Beyreuther K, et al. The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron 9(1): 129-137 (1992).
76. Murase K, Nabeshima T, Robitaille Y, Quirion R, Ogawa M, Hayashi K. NGF level of is not decreased in the serum, brain-spinal fluid, hippocampus, or parietal cortex of individuals with Alzheimer's disease. Biochem Biophys Res Commun 193(1): 198-203 (1993).
77. Narisawa-Saito M, Wakabayashi K, Tsuji S, Takahashi H, Nawa H. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Neuroreport 7(18): 2925-8 (1996).
78. Schulte-Herbruggen O, Eckart S, Deicke U, Kuhl A, Otten U, Danker-Hopfe H, et al. Age-dependent time course of cerebral brain-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 in APP23 transgenic mice. J Neurosci Res 86(12): 2774-2783 (2008).
79. Yosef N, Ubogu EE. GDNF restores human blood-nerve barrier function via RET tyrosine kinase-mediated cytoskeletal reorganization. Microvasc Res 83(3): 298-310 (2012).
80. Igarashi Y, Utsumi H, Chiba H, Yamada-Sasamori Y, Tobioka H, Kamimura Y, et al. Glial cell line-derived neurotrophic factor induces barrier function of endothelial cells forming the bloodbrain barrier. Biochem Biophys Res Commun 261(1): 108-112 (1999).
81. Zhang DK, He FQ, Li TK, Pang XH, Cui de J, Xie Q, et al. Glialderived neurotrophic factor regulates intestinal epithelial barrier function and inflammation and is therapeutic for murine colitis. J Pathol 222(2): 213-222 (2010).
82. Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M, et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 266(5187): 1062-4 (1994).
83. Arenas E, Trupp M, Akerud P, Ibanez CF. GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron 15(6): 1465-1473 (1995).
84. Peterziel H, Unsicker K, Krieglstein K. TGFbeta induces GDNF responsiveness in neurons by recruitment of GFRalpha1 to the plasma membrane. J Cell Biol 159(1): 157-167 (2002).
85. Straten G, Eschweiler GW, Maetzler W, Laske C, Leyhe T. Glial cell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer's disease and normal controls. J Alzheimers Dis 18(2): 331-7 (2009).
86. Straten G, Saur R, Laske C, Gasser T, Annas P, Basun H, et al. Influence of Lithium Treatment on GDNF Serum and CSF Concentrations in Patients with Early Alzheimer's Disease. Curr Alzheimer Res 8(8): 853-9 (2011).
87. Schneider A, Kruger C, Steigleder T, Weber D, Pitzer C, Laage R, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 115(8): 2083-2098 (2005).
88. Deindl E, Zaruba MM, Brunner S, Huber B, Mehl U, Assmann G, et al. G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis. FASEB J 20(7): 956-8 (2006).
89. Plenz G, Eschert H, Beissert S, Arps V, Sindermann JR, Robenek H, et al. Alterations in the vascular extracellular matrix of granulocyte macrophage colony-stimulating factor (GM-CSF) - deficient mice. FASEB J 17(11): 1451-7 (2003).
90. Bussolino F, Wang JM, Defilippi P, Turrini F, Sanavio F, Edgell CJ, et al. Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature 337(6206): 471-3 (1989).
91. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3(7): 687-694 (2002).
92. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 344(6263): 254-7 (1990).
93. World Health Organisation, Tenth revision of the International Classification of Diseases. Chapter 5 (F): Mental and behaviourl disorders (including disorders of psychological development). Clinical Descriptions and Diagnostic Guidelines. World Health Organisation, Geneva: (1992).
94. Laske C, Stellos K, Stransky E, Leyhe T, Gawaz M. Decreased plasma levels of granulocyte-colony stimulating factor (G-CSF) in patients with early Alzheimer's disease. J Alzheimers Dis 17(1): 115-123 (2009).
95. Goldberg MA, Schneider TJ. Similarities between the oxygensensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 269(6): 4355-9 (1994).
96. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124(1): 175-189 (2006).
97. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18(14): 3964-3972 (1999).
98. Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M, et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 22(3): 377-384 (2004).
99. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22(4): 201-7 (2001).
100. Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 193(9): 1005-1014 (2001).
101. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417(6892): 954-8 (2002).
102. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130(4): 691-703 (2007).
103. Sondell M, Lundborg G, Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 19(14): 5731-5740 (1999).
104. Silverman WF, Alfahel-Kakunda A, Dori A, Barker JL. Separation of dorsal and ventral dopaminergic neurons from embryonic rat mesencephalon by buoyant density fractionation: disassembling pattern in the ventral midbrain. J Neurosci Methods 89(1): 1-8 (1999).
105. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34(4): 383-394 (2003).
106. Matsuzaki H, Tamatani M, Yamaguchi A, Namikawa K, Kiyama H, Vitek MP, et al. Vascular endothelial growth factor rescues hippocampal neurons from glutamate-induced toxicity: signal transduction cascades. FASEB J 15(7): 1218-1220 (2001).
107. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 99(18): 11946-11950 (2002).
108. Yourey PA, Gohari S, Su JL, Alderson RF. Vascular endothelial cell growth factors promote the in vitro development of rat photoreceptor cells. J Neurosci 20(18): 6781-8 (2000).
109. Zhu Y, Jin K, Mao XO, Greenberg DA. Vascular endothelial growth factor promotes proliferation of cortical neuron precursors by regulating E2F expression. FASEB J 17(2): 186-193 (2003).
110. Louissaint A, Jr., Rao S, Leventhal C, Goldman SA. Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. Neuron 34(6): 945-960 (2002).
111. Abrous DN, Koehl M, Le Moal M. Adult neurogenesis: from precursors to network and physiology. Physiol Rev 85(2): 523-569 (2005).
112. Ogunshola OO, Antic A, Donoghue MJ, Fan SY, Kim H, Stewart WB, et al. Paracrine and autocrine functions of neuronal vascular endothelial growth factor (VEGF) in the central nervous system. J Biol Chem 277(13): 11410-11415 (2002).
113. Forstreuter F, Lucius R, Mentlein R. Vascular endothelial growth factor induces chemotaxis and proliferation of microglial cells. J Neuroimmunol 132(1-2): 93-8 (2002).
114. Loeffler S, Fayard B, Weis J, Weissenberger J. Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer 115(2): 202-213 (2005).
115. Plaschke K, Staub J, Ernst E, Marti HH. VEGF overexpression improves mice cognitive abilities after unilateral common carotid artery occlusion. Exp Neurol 214(2): 285-292 (2008).
116. Wen Y, Yang S, Liu R, Brun-Zinkernagel AM, Koulen P, Simpkins JW. Transient cerebral ischemia induces aberrant neuronal cell cycle re-entry and Alzheimer's disease-like tauopathy in female rats. J Biol Chem 279(21): 22684-22692 (2004).
117. Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A, et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging 23(2): 237-243 (2002).
118. Mateo I, Llorca J, Infante J, Rodriguez-Rodriguez E, Fernandez- Viadero C, Pena N, et al. Low serum VEGF levels are associated with Alzheimer's disease. Acta Neurol Scand 116(1): 56-58 (2007).
119. Broudy VC, Kovach NL, Bennett LG, Lin N, Jacobsen FW, Kidd PG. Human umbilical vein endothelial cells display high-affinity ckit receptors and produce a soluble form of the c-kit receptor. Blood 83(8): 2145-2152 (1994).
120. Koenig A, Yakisan E, Reuter M, Huang M, Sykora KW, Corbacioglu S, et al. Differential regulation of stem cell factor mRNA expression in human endothelial cells by bacterial pathogens: an in vitro model of inflammation. Blood 83(10): 2836-43 (1994).
121. Broudy VC, Lin NL, Sabath DF, Papayannopoulou T, Kaushansky K. Human platelets display high-affinity receptors for thrombopoietin. Blood 89(6): 1896-1904 (1997).
122. Wang CH, Anderson N, Li SH, Szmitko PE, Cherng WJ, Fedak PW, et al. Stem cell factor deficiency is vasculoprotective: unraveling a new therapeutic potential of imatinib mesylate. Circ Res 99(6): 617-625 (2006).
123. Wang CH, Verma S, Hsieh IC, Hung A, Cheng TT, Wang SY, et al. Stem cell factor attenuates vascular smooth muscle apoptosis and increases intimal hyperplasia after vascular injury. Arterioscler Thromb Vasc Biol 27(3): 540-7 (2007).
124. Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 9(4): 287-300 (2006).
125. Zhang SC, Fedoroff S. Expression of stem cell factor and c-kit receptor in neural cells after brain injury. Acta Neuropathol 97(4): 393-8 (1999).
126. Jin K, Mao XO, Sun Y, Xie L, Greenberg DA. Stem cell factor stimulates neurogenesis in vitro and in vivo. J Clin Invest 110(3): 311-9 (2002).
127. Erlandsson A, Larsson J, Forsberg-Nilsson K. Stem cell factor is a chemoattractant and a survival factor for CNS stem cells. Exp Cell Res 301(2): 201-210 (2004).
128. Corti S, Locatelli F, Strazzer S, Salani S, Del Bo R, Soligo D, et al. Modulated generation of neuronal cells from bone marrow by expansion and mobilization of circulating stem cells with in vivo cytokine treatment. Exp Neurol 177(2): 443-452 (2002).
129. Li B, Gonzalez-Toledo ME, Piao CS, Gu A, Kelley RE, Zhao LR. Stem cell factor and granulocyte colony-stimulating factor reduce beta-amyloid deposits in the brains of APP/PS1 transgenic mice. Alzheimers Res Ther 3(2): 8 (2011).
130. Dhandapani KM, Wade FM, Wakade C, Mahesh VB, Brann DW. Neuroprotection by stem cell factor in rat cortical neurons involves AKT and NFkappaB. J Neurochem 95(1): 9-19 (2005).
131. Zhang SC, Fedoroff S. Modulation of microglia by stem cell factor. J Neurosci Res 53(1): 29-37 (1998).
132. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19(8): 312-8 (1996).
133. Chen X, Fu W, Tung CE, Ward NL. Angiopoietin-1 induces neurite outgrowth of PC12 cells in a Tie2-independent, beta1- integrin-dependent manner. Neurosci Res 64(4): 348-354 (2009).
134. Laske C, Stellos K, Stransky E, Seizer P, Akcay O, Eschweiler GW, et al. Decreased plasma and cerebrospinal fluid levels of stem cell factor in patients with early Alzheimer's disease. J Alzheimers Dis 15(3): 451-460 (2008).
135. Laske C, Sopova K, Hoffmann N, Stransky E, Hagen K, Fallgatter AJ, et al. Stem cell factor plasma levels are decreased in Alzheimer's disease patients with fast cognitive decline after oneyear follow-up period: the Pythia-study. J Alzheimers Dis 26(1): 39-45 (2011).
136. Doody RS, Massman P, Dunn JK. A method for estimating progression rates in Alzheimer disease. Arch Neurol 58(3): 449-454 (2001).
137. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 11(2): 131-145 (2003).
138. Leyhe T, Hoffmann N, Stransky E, Laske C. Increase of SCF plasma concentration during donepezil treatment of patients with early Alzheimer's disease. Int J Neuropsychopharmacol 12(10): 1319-1326 (2009).
139. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10(8): 858-864 (2004).
140. Kucia M, Dawn B, Hunt G, Guo Y, Wysoczynski M, Majka M, et al. Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction. Circ Res 95(12): 1191-1199 (2004).
141. Stellos K, Langer H, Daub K, Schoenberger T, Gauss A, Geisler T, et al. Platelet-derived stromal cell-derived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells. Circulation 117(2): 206-215 (2008).
142. Rempel SA, Dudas S, Ge S, Gutierrez JA. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res 6(1): 102-111 (2000).
143. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 203(9): 2201-2213 (2006).
144. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, et al. Defects of B-cell lymphopoiesis and bonemarrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382(6592): 635-8 (1996).
145. Doitsidou M, Reichman-Fried M, Stebler J, Koprunner M, Dorries J, Meyer D, et al. Guidance of primordial germ cell migration by the chemokine SDF-1. Cell 111(5): 647-659 (2002).
146. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393(6685): 591-4 (1998).
147. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393(6685): 595-9 (1998).
148. Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 28(7): 299-307 (2007).
149. Stumm RK, Rummel J, Junker V, Culmsee C, Pfeiffer M, Krieglstein J, et al. A dual role for the SDF-1/CXCR4 chemokine receptor system in adult brain: isoform-selective regulation of SDF- 1 expression modulates CXCR4-dependent neuronal plasticity and cerebral leukocyte recruitment after focal ischemia. J Neurosci 22(14): 5865-5878 (2002).
150. Pujol F, Kitabgi P, Boudin H. The chemokine SDF-1 differentially regulates axonal elongation and branching in hippocampal neurons. J Cell Sci 118(Pt 5): 1071-1080 (2005).
151. Huang J, Li Y, Tang Y, Tang G, Yang GY, Wang Y. CXCR4 antagonist AMD3100 protects blood-brain barrier integrity and reduces inflammatory response after focal ischemia in mice. Stroke 44(1): 190-7 (2013).
152. Man S, Tucky B, Cotleur A, Drazba J, Takeshita Y, Ransohoff RM. CXCL12-induced monocyte-endothelial interactions promote lymphocyte transmigration across an in vitro blood-brain barrier. Sci Transl Med 4(119): 119ra14 (2012).
153. Cruz-Orengo L, Holman DW, Dorsey D, Zhou L, Zhang P, Wright M, et al. CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity. J Exp Med 208(2): 327-339 (2011).
154. McCandless EE, Piccio L, Woerner BM, Schmidt RE, Rubin JB, Cross AH, et al. Pathological expression of CXCL12 at the bloodbrain barrier correlates with severity of multiple sclerosis. Am J Pathol 172(3): 799-808 (2008).
155. McCandless EE, Budde M, Lees JR, Dorsey D, Lyng E, Klein RS. IL-1R signaling within the central nervous system regulates CXCL12 expression at the blood-brain barrier and disease severity during experimental autoimmune encephalomyelitis. J Immunol 183(1): 613-620 (2009).
156. Laske C, Stellos K, Eschweiler GW, Leyhe T, Gawaz M. Decreased CXCL12 (SDF-1) plasma levels in early Alzheimer's disease: a contribution to a deficient hematopoietic brain support? J Alzheimers Dis 15(1): 83-95 (2008).
157. Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 282(5388): 468-471 (1998).
158. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6(4): 460-3 (2000).
159. Daly C, Wong V, Burova E, Wei Y, Zabski S, Griffiths J, et al. Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev 18(9): 1060-1071 (2004).
160. Hori S, Ohtsuki S, Hosoya K, Nakashima E, Terasaki T. A pericyte-derived angiopoietin-1 multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tie-2 activation in vitro. J Neurochem 89(2): 503-513 (2004).
161. Zhang ZG, Zhang L, Tsang W, Soltanian-Zadeh H, Morris D, Zhang R, et al. Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia. J Cereb Blood Flow Metab 22(4): 379-392 (2002).
162. Valable S, Bellail A, Lesne S, Liot G, Mackenzie ET, Vivien D, et al. Angiopoietin-1-induced PI3-kinase activation prevents neuronal apoptosis. FASEB J 17(3): 443-5 (2003).
163. Schreitmuller B, Leyhe T, Stransky E, Kohler N, Laske C. Elevated angiopoietin-1 serum levels in patients with Alzheimer's disease. Int J Alzheimers Dis 2012: 324016 (2012).
164. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 83(3): 233-240 (1998).
165. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277(5322): 55-60 (1997).
166. Zhu Y, Lee C, Shen F, Du R, Young WL, Yang GY. Angiopoietin- 2 facilitates vascular endothelial growth factor-induced angiogenesis in the mature mouse brain. Stroke 36(7): 1533-7 (2005).
167. Liu XS, Chopp M, Zhang RL, Hozeska-Solgot A, Gregg SC, Buller B, et al. Angiopoietin 2 mediates the differentiation and migration of neural progenitor cells in the subventricular zone after stroke. J Biol Chem 284(34): 22680-9 (2009).
168. Marteau L, Valable S, Divoux D, Roussel SA, Touzani O, Mackenzie ET, et al. Angiopoietin-2 is vasoprotective in the acute phase of cerebral ischemia. J Cereb Blood Flow Metab 33(3): 389-395 (2013).
169. Thirumangalakudi L, Samany PG, Owoso A, Wiskar B, Grammas P. Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. J Alzheimers Dis 10(1): 111-8 (2006).
170. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 1(2): 213-225 (2004).
171. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13(11): 1359-1362 (2007).
172. Laske C, Stellos K, Hoffmann N, Stransky E, Straten G, Eschweiler GW, et al. Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients. Int J Neuropsychopharmacol 14(3): 399-404 (2011).
173. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 15(3): 331-7 (2009).
174. Shin JW, Lee JK, Lee JE, Min WK, Schuchman EH, Jin HK, et al. Combined effects of hematopoietic progenitor cell mobilization from bone marrow by granulocyte colony stimulating factor and AMD3100 and chemotaxis into the brain using stromal cell-derived factor-1alpha in an Alzheimer's disease mouse model. Stem Cells 29(7): 1075-1089 (2011).
175. Schabitz WR, Kollmar R, Schwaninger M, Juettler E, Bardutzky J, Scholzke MN, et al. Neuroprotective effect of granulocyte colonystimulating factor after focal cerebral ischemia. Stroke 34(3): 745-751 (2003).
176. Shyu WC, Lin SZ, Lee CC, Liu DD, Li H. Granulocyte colonystimulating factor for acute ischemic stroke: a randomized controlled trial. CMAJ 174(7): 927-33 (2006).
177. Tsai KJ, Tsai YC, Shen CK. G-CSF rescues the memory impairment of animal models of Alzheimer's disease. J Exp Med 204(6): 1273-1280 (2007).
178. Sanchez-Ramos J, Song S, Sava V, Catlow B, Lin X, Mori T, et al. Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice. Neurosci 163(1): 55-72 (2009).
179. Sanchez-Ramos J, Cimino C, Avila R, Rowe A, Chen R, Whelan G, et al. Pilot study of granulocyte-colony stimulating factor for treatment of Alzheimer's disease. J Alzheimers Dis 31(4): 843-855 (2012).
180. Wang P, Xie ZH, Guo YJ, Zhao CP, Jiang H, Song Y, et al. VEGFinduced angiogenesis ameliorates the memory impairment in APP transgenic mouse model of Alzheimer's disease. Biochem Biophys Res Commun 411(3): 620-6 (2011).
181. Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 111(12): 1843-1851 (2003).
182. Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11(5): 551-5 (2005).
183. Mandel RJ. CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr Opin Mol Ther 12(2): 240-7 (2010).
184. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7(5): 695-702 (1991).